{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:58:52Z","timestamp":1780948732674,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00774-026-01696-1","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T04:58:53Z","timestamp":1771390733000},"page":"375-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteoporosis risk with sodium\u2013glucose cotransporter 2 inhibitors versus thiazolidinediones in older women with diabetes"],"prefix":"10.1007","volume":"44","author":[{"given":"Hyeon Jeong","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7349-9880","authenticated-orcid":false,"given":"Pusoon","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,18]]},"reference":[{"key":"1696_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster J-Y, Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF) (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344","journal-title":"Osteoporos Int"},{"key":"1696_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Willers C, Borgstr\u00f6m F (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82","journal-title":"Arch Osteoporos"},{"key":"1696_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.mayocp.2014.09.011","volume":"90","author":"A Singer","year":"2015","unstructured":"Singer A, Exuzides A, Spangler L, O\u2019Malley C, Colby C, Johnston K, Agodoa I, Baker J, Kagan RR (2015) Burden of illness for osteoporotic fractures compared with other serious diseases among postmenopausal women in the United States. Mayo Clin Proc 90:53\u201362","journal-title":"Mayo Clin Proc"},{"key":"1696_CR4","unstructured":"International Diabetes Federation (2025) IDF diabetes atlas 11th edition\u20142025. IDF_Diabetes_Atlas_11th_Edition_2025_WEB.pdf. P45. Accessed 15 Oct 2025"},{"key":"1696_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.918350","volume":"13","author":"B Dong","year":"2022","unstructured":"Dong B, Lv R, Wang J, Che L, Wang Z, Huai Z, Wang Y, Xu L (2022) The extraglycemic effect of SGLT-2is on mineral and bone metabolism and bone fracture. Front Endocrinol 13:918350","journal-title":"Front Endocrinol"},{"key":"1696_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01517","volume":"9","author":"Y Ye","year":"2019","unstructured":"Ye Y, Zhao C, Liang J, Yang Y, Yu M, Qu X (2019) Effect of sodium-glucose co-transporter 2 inhibitors on bone metabolism and fracture risk. Front Pharmacol 9:1517","journal-title":"Front Pharmacol"},{"key":"1696_CR7","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian JP, Watts NB, Usiskin K, Polidori D, Fung A, Sullivan D, Rosenthal N (2016) Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J Clin Endocrinol Metab 101:44\u201351","journal-title":"J Clin Endocrinol Metab"},{"key":"1696_CR8","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1111\/dom.13631","volume":"21","author":"S Gallo","year":"2019","unstructured":"Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, Lauring B, Terra SG (2019) Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial. Diabetes Obes Metab 21:1027\u20131036","journal-title":"Diabetes Obes Metab"},{"key":"1696_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.249","volume":"18","author":"H Hauner","year":"2002","unstructured":"Hauner H (2002) The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18:S10\u201315","journal-title":"Diabetes Metab Res Rev"},{"key":"1696_CR10","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1463-1326.2008.00931.x","volume":"11","author":"A Grey","year":"2009","unstructured":"Grey A (2009) Thiazolidinedione-induced skeletal fragility\u2013mechanisms and implications. Diabetes Obes Metab 11:275\u2013284","journal-title":"Diabetes Obes Metab"},{"key":"1696_CR11","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1210\/jc.2006-2646","volume":"92","author":"A Grey","year":"2007","unstructured":"Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, Reid IR (2007) The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 92:1305\u20131310","journal-title":"J Clin Endocrinol Metab"},{"key":"1696_CR12","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.1210\/jc.2005-2226","volume":"91","author":"AV Schwartz","year":"2006","unstructured":"Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, Strotmeyer ES, Resnick HE, Carbone L, Beamer BA, Park SW, Lane NE, Harris TB, Cummings SR (2006) Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 91:3349\u20133354","journal-title":"J Clin Endocrinol Metab"},{"key":"1696_CR13","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1007\/s00125-015-3660-2","volume":"58","author":"EO Billington","year":"2015","unstructured":"Billington EO, Grey A, Bolland MJ (2015) The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis. Diabetologia 58:2238\u20132246","journal-title":"Diabetologia"},{"key":"1696_CR14","unstructured":"HIRA Bigdata Open Portal (2024) Medical statistics information. https:\/\/opendata.hira.or.kr\/op\/opc\/olap3thDsInfoTab2.do. Accessed 26 Dec 2024"},{"key":"1696_CR15","doi-asserted-by":"crossref","first-page":"783","DOI":"10.56786\/PHWR.2023.16.25.1","volume":"16","author":"E Song","year":"2023","unstructured":"Song E, Park E, Choe SA, Park J, Song BM, Han K, Park HY (2023) How do Korean women manage menstrual or menopausal symptoms: 2022 women\u2019s health survey for sexual and reproductive health. Public Health Weekly Rep 16:783\u2013800","journal-title":"Public Health Weekly Rep"},{"key":"1696_CR16","doi-asserted-by":"publisher","DOI":"10.4178\/epih\/e2014008","volume":"36","author":"K Kim","year":"2014","unstructured":"Kim K, Kim JA, Kim S (2014) A guide for the utilization of health insurance review and assessment service national patient samples. Epidemiol Health 36:e2014008","journal-title":"Epidemiol Health"},{"key":"1696_CR17","unstructured":"Health Insurance Review & Assessment Service (2025) HIRA research data user guide. file:\/\/\/C:\/Users\/admin\/Downloads\/%EC%97%B0%EA%B5%AC%EA%B3%BC%EC%A0%9C%20%EC%9D%B4%EC%9A%A9%20%EA%B0%80%EC%9D%B4%EB%93%9C%20(11).pdf. Accessed 9 Apr 2025"},{"key":"1696_CR18","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3390\/medicina60030393","volume":"60","author":"A Wikarek","year":"2024","unstructured":"Wikarek A, Grabarczyk M, Klimek K, Janoska-Gawro\u0144ska A, Suchodolska M, Holecki M (2024) Effect of drugs used in pharmacotherapy of type 2 diabetes on bone density and risk of bone fractures. Medicina Kaunas 60:393","journal-title":"Medicina Kaunas"},{"key":"1696_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00774-022-01372-0","volume":"41","author":"J Tamaki","year":"2023","unstructured":"Tamaki J, Ogawa S, Fujimori K, Ishii S, Nakatoh S, Okimoto N, Kamiya K, Iki M (2023) Hip and vertebral fracture risk after initiating antidiabetic drugs in Japanese elderly: a nationwide study. J Bone Miner Metab 41:29\u201340","journal-title":"J Bone Miner Metab"},{"key":"1696_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676\u2013682","journal-title":"Am J Epidemiol"},{"key":"1696_CR21","unstructured":"The Korean Society for Bone and Mineral Research (2024) 2024 Guidelines for the diagnosis and management of osteoporosis. https:\/\/www.ksbmr.org\/bbs\/?number=1672&mode=view&code=notice. Accessed 26 Dec 2024"},{"key":"1696_CR22","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1093\/aje\/kwj047","volume":"163","author":"T Kurth","year":"2006","unstructured":"Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, Robins JM (2006) Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 163:262\u2013270","journal-title":"Am J Epidemiol"},{"key":"1696_CR23","doi-asserted-by":"publisher","first-page":"895","DOI":"10.3803\/EnM.2021.1026","volume":"36","author":"J Ha","year":"2021","unstructured":"Ha J, Lim Y, Kim MK, Kwon HS, Song KH, Ko SH, Kang MI, Moon SD, Baek KH (2021) Comparison of the effects of various antidiabetic medication on bone mineral density in patients with type 2 diabetes mellitus. Endocrinol Metab 36:895\u2013903","journal-title":"Endocrinol Metab"},{"key":"1696_CR24","unstructured":"Korean Diabetes Association (2025) Diabetes fact sheet in Korea 2024. https:\/\/www.diabetes.or.kr\/bbs\/?code=fact_sheet&mode=view&number=2792&page=1&code=fact_sheet. Accessed 11 Mar 2025"},{"key":"1696_CR25","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes\u20142025. Diabetes Care 48:S181\u2013S206","journal-title":"Diabetes Care"},{"key":"1696_CR26","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.2337\/dc25-S004","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee (2025) Comprehensive medical evaluation and assessment of comorbidities: Standards of care in diabetes\u20132025. Diabetes Care 48:S59\u2013S85","journal-title":"Diabetes Care"},{"key":"1696_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N, Diab DL, Eldeiry LS, Farooki A, Harris ST, Hurley DL, Kelly J, Lewiecki EM, Pessah-Pollack R, McClung M, Wimalawansa SJ, Watts NB (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis\u20132020 update. Endocr Pract 26:1\u201346","journal-title":"Endocr Pract"},{"key":"1696_CR28","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-024-01466-4","volume":"19","author":"T Das","year":"2024","unstructured":"Das T, Biswas MAAJ, Mondal P, Sarker S, Lim HJJ (2024) Osteoporosis incidence and its associated factors in the older Korean population: findings from a population-based cohort study. Arch Osteoporos 19:111","journal-title":"Arch Osteoporos"},{"key":"1696_CR29","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1172\/JCI28550","volume":"116","author":"MN Weitzmann","year":"2006","unstructured":"Weitzmann MN, Pacifici R (2006) Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 116:1186\u20131194","journal-title":"J Clin Invest"},{"key":"1696_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-013-0328-0","volume":"15","author":"IEM Bultink","year":"2013","unstructured":"Bultink IEM, Lems WF (2013) Osteoarthritis and osteoporosis: what is the overlap? Curr Rheumatol Rep 15:328","journal-title":"Curr Rheumatol Rep"},{"key":"1696_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-019-0836-7","volume":"21","author":"G Adami","year":"2019","unstructured":"Adami G, Saag KG (2019) Osteoporosis pathophysiology, epidemiology, and screening in rheumatoid arthritis. Curr Rheumatol Rep 21:34","journal-title":"Curr Rheumatol Rep"},{"key":"1696_CR32","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1111\/jgh.15879","volume":"37","author":"DH Park","year":"2022","unstructured":"Park DH, Seo SI, Lee KJ, Kim J, Kim Y, Seo WW, Lee HS, Shin WG, Yoo JJ (2022) Long-term proton pump inhibitor use and risk of osteoporosis and hip fractures: a nationwide population-based and multicenter cohort study using a common data model. J Gastroenterol Hepatol 37:1534\u20131543","journal-title":"J Gastroenterol Hepatol"},{"key":"1696_CR33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.23876\/j.krcp.20.132","volume":"39","author":"TJ Oh","year":"2020","unstructured":"Oh TJ, Moon J-Y, Hur KY, Ko SH, Kim HJ, Kim T, Lee DW, Moon MK, Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology (2020) Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement. Kidney Res Clin Pract 39:269\u2013283","journal-title":"Kidney Res Clin Pract"},{"key":"1696_CR34","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nm.3159","volume":"19","author":"M Ahmadian","year":"2013","unstructured":"Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM (2013) PPAR\u03b3 signaling and metabolism: the good, the bad and the future. Nat Med 19:557\u2013566","journal-title":"Nat Med"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01696-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-026-01696-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01696-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:10:21Z","timestamp":1780945821000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00774-026-01696-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,18]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1696"],"URL":"https:\/\/doi.org\/10.1007\/s00774-026-01696-1","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,18]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Institutional Review Board of Inje University (INJE 2025\u201301-007), which waived the requirement for informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Ethics and Consent to Participate Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}